Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

<p><strong>Background & Aims</strong> Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel disea...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Elsevier 2019

Gelijkaardige items

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
door: Williamson, K, et al.
Gepubliceerd in: (2018)

Vedolizumab for the treatment of chronic pouchitis
door: Travis, S, et al.
Gepubliceerd in: (2023)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
door: Renske W. M. Pauwels, et al.
Gepubliceerd in: (2020-12-01)

Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
door: Suzanne I. Anjie, et al.
Gepubliceerd in: (2024-02-01)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
door: Matthew Luzentales-Simpson, et al.
Gepubliceerd in: (2021-02-01)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
door: Pulusu, S, et al.
Gepubliceerd in: (2018)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
door: Kothari M, et al.
Gepubliceerd in: (2015-08-01)

Vedolizumab for inflammatory bowel diseasesI
door: Igor L. Khalif, et al.
Gepubliceerd in: (2018-08-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
door: A. O. Golovenko, et al.
Gepubliceerd in: (2018-10-01)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
door: Judy A. Trieu, et al.
Gepubliceerd in: (2017-12-01)

Vedolizumab-Induced Liver Injury
door: Miguel Mascarenhas Saraiva, et al.
Gepubliceerd in: (2020-12-01)

Vedolizumab in paediatric Inflammatory Bowel Disease: A retrospective multi-centre experience From the paediatric IBD Porto Group of ESPGHAN
door: Ledder, O, et al.
Gepubliceerd in: (2017)

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
door: Ledder, O, et al.
Gepubliceerd in: (2017)

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
door: Beatriz Gros, et al.
Gepubliceerd in: (2024-07-01)

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
door: de Vries, E, et al.
Gepubliceerd in: (2016)

Vedolizumab in Inflammatory Bowel Disease: West versus East
door: Prasanta Debnath, et al.
Gepubliceerd in: (2021-01-01)

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
door: Martine Walmsley, et al.
Gepubliceerd in: (2024-06-01)

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
door: Bhayat, F, et al.
Gepubliceerd in: (2017)

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
door: Ledder, O, et al.
Gepubliceerd in: (2017)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
door: Feagan, B, et al.
Gepubliceerd in: (2017)

Clinical efficacy of vedolizumab for inflammatory bowel disease
door: Liu Sixue, Zhong Wa, Lin Ying, Xia Zhongsheng, Zhong Yingqiang
Gepubliceerd in: (2022-10-01)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
door: Asaf Levartovsky, et al.
Gepubliceerd in: (2022-06-01)

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
door: Travis, S, et al.
Gepubliceerd in: (2018)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
door: Feagan, BG, et al.
Gepubliceerd in: (2018)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
door: Abdulaziz Saad Alshahrani, et al.
Gepubliceerd in: (2023-09-01)

Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
door: S. K. Zyryanov, et al.
Gepubliceerd in: (2018-05-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
door: Kira L. Newman, et al.
Gepubliceerd in: (2023-03-01)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
door: Merve Sivridaş, et al.
Gepubliceerd in: (2023-03-01)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
door: Fares Ayoub, et al.
Gepubliceerd in: (2022-04-01)

Introducing vedolizumab to clinical practice: who, when and how?
door: Bryant, R, et al.
Gepubliceerd in: (2015)

A product review of vedolizumab in inflammatory bowel disease
door: Robert Battat, et al.
Gepubliceerd in: (2019-10-01)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
door: Benjamin Crooks, et al.
Gepubliceerd in: (2020-03-01)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
door: Feagan, B, et al.
Gepubliceerd in: (2017)

Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review
door: Shahed Kamal, et al.
Gepubliceerd in: (2024-08-01)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
door: Bhayat, F, et al.
Gepubliceerd in: (2017)

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
door: Bye, W, et al.
Gepubliceerd in: (2017)

Vedolizumab in Crohn Disease genesis-sefh drug evaluation report
door: Jenifer González Chávez, et al.
Gepubliceerd in: (2015-09-01)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
door: Eddie Y. Liu, et al.
Gepubliceerd in: (2017-01-01)

Take vedolizumab home: transition from intravenous to subcutaneous treatment
door: Kaituo Huang, et al.
Gepubliceerd in: (2024-05-01)

Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis
door: Thomas Schiestel
Gepubliceerd in: (2023-03-01)